Prevalence of Hepatitis G Virus in
Blood Donors and Recipients
Hasan KAYA*, Fuat ERDEM*, M. Fevzi POLAT**,***, Ýlhami KIKI*,
Mehmet GÜNDOÐDU*, Fatih ÖZÇÝÇEK*
* Department of Haematology, Faculty of Medicine, Atatürk Univeresity,
** Department of Biochemistriy, Faculty of Medicine, Atatürk Univeresity,
*** Department of Biotechnology Application and Research Center, Faculty of Medicine, Atatürk University, Erzurum, TURKEY
ABSTRACT
We evaluated the prevalence of hepatitis G virus (HGV) infection in patients who had received multiple blood
components and in blood donors and the possible coinfection with hepatitis C virus (HCV).
Eighty patients who had received multiple blood components and 70 eligible blood donors, as controls were
included in this study. HGV RNA was determined by reverse polymerase chain reaction in serum. HGV-RNA was
detected in three (3.7%) of patients and in one (1.4%) of controls. Statistical analysis showed no difference between the groups (p> 0.05). HGV and HCV coinfection was not observed in both patient and control groups. Although the most important risk factor for HGV infection was found to be blood transfusions in various studies, this
study showed that there is not significant relationship between blood components transfusion and HGV infection.
Key Words: Hepatitis G virus, Blood donors.
ÖZET
Kan Ürünü Verici ve Alýcýlarýnda Hepatit G Virüs Prevalansý
Bu yazýda, çok sayýda kan ürünü alan hastalar ve vericilerinde hepatit G virüs prevalansýný ve hepatit C virüs
(HCV) infeksiyonunu inceledik.
Çok sayýda kan ürünü alan 80 hasta ve kontrol grubu olarak 70 kan ürünü vericisi çalýþmaya alýndý. HGV RNA
serumda PCR ile belirlendi. Hastalarýn üçünde (%3.7) ve vericilerin birinde (%1.4) HGV RNA pozitif bulundu. Ýstatistik analiz gruplar arasýnda fark göstermedi (p> 0.05). Her iki grupta da HGV ve HCV infeksiyon birlikteliði
gösterilmedi. Her ne kadar pek çok çalýþmada HGV infeksiyonu için en önemli risk faktörü kan transfüzyonu olarak gösterilmekte ise de bu çalýþmada bu iliþki gösterilemedi.
Anahtar Kelimeler: Hepatit G virüs, Kan ürünü.
Turk J Haematol 2003;20(2): 85-90
Received: 07.10.2002
Accepted: 05.02.2003
85
Kaya H, Erdem F, Polat MF, Kýký Ý, Gündoðdu M, Özçiçek F.
Prevalence of Hepatitis G Virus in Blood Donors and Recipients
INTRODUCTION
Infection with blood-borne viruses is common
among patient who had received blood components.
Recently, two independent laboratories have identified
a newly proposed hepatotropic RNA viral agent named
either GB virus-C (GBV-C) or hepatitis G virus
(HGV). The amino acid sequences of these viruses
share 95% homology and they are considered to be different isolates of the same virus in the Flaviviridae family sharing large structural and biological similarities
with hepatitis C virus (HCV)[1,2].
It now seems that the transmission of HGV is primarily by the parenteral route, especially by transfusion of contaminated blood components[1,3-9]. But, the
epidemiology of HGV infection, including determination of modes of transmission of HGV must still be a
subject of research to answer unresolved questions.
This study was carried in order to determine the prevalence of HGV in selected groups of Turkish patients
who had received multiple blood components and eligible blood donors.
MATERIALS and METHODS
Study population: We screened the presence of
HGV-RNA in the sera of 80 patients (mean age ± SD:
46.0 ± 18.4 years, range 14-80 years, 43M/34F) with different diseases (acute myeloblastic leukemia 12, acute
lymphoblastic leukemia 11, chronic lymphocytic leukemia 5, Hodgkin’s disease 6, non-Hodgkin’s disease
12, myelodisplastic syndrome 3, multiple myeloma 3,
aplastic anemia 2, hemophilia 5, gastric cancer 14,
pancreatic carcinoma 2, colon cancer 4, ovarian carcinoma 3) who had received blood components. We also
analyzed sera from 70 age-and sex-matched healthy
subjects, as control group (mean age ± SD: 45.4 ± 18.4
years, range 16-79 years, 39M/31F). The criteria for
controls were that they evidenced no risk factor for blood-transmissible viruses and that they had never received a transfusion. At least one month had passed between the first transfusion and blood sampling. The
average duration of previous transfusions was five years. The characteristics of all study population were
showed in Table 1.
The exposure to blood components is expressed in
blood units (1 blood unit is defined as 1 unit of packet
red cells or platelets or fresh frozen plasma derived
from a single donor). The median number of units
transfused was 6.8 per patient (1-50 Units).
Sera from patients and controls were rapidly frozen
and stored at -75°C, until required parallel assays. The
status for coinfection with HCV and for the possibility
of liver diseases was determined hepatitis C virus antibody (anti-HCV) in all.
Determination of HGV RNA by reverse polymerase chain reaction assay. HGV RNA was determined by
RT-PCR with nested primers derived from conserved
regions of the 5’-noncoding region of the HGV genome by the method reported elsewhere[10].
RNA was extracted from each 100 µl serum by
using High Pure Viral Nucleic Acid (Boehringer,
Mannheim, Germany). cDNA’s were synthesized by
using 5’-CCT ATT GGT CAA GAG AGA CAT-3’ antisense primer (#G75) AMV reverse transcriptase (RT)
enzyme in a thermal cycler (Techne PHC-3,UK) at
42°C for one hour. From these cDNAs, 5’-CAG GGT
TGG TAG GTC GTA ATT CC-3’ sense and mentioned
Table 1. Demographic and serologic profile of patients and controls
Age mean ± SD (range)
Sex (M: F)
Number of transfusion (average)
Patients (n= 80)
Controls (n= 70)
46.0 ± 18.4 (14-80)
45.4 ± 18.4 (16-79)
43:34
39:31
6.8 Unit
0
HGV RNA positive
3 (3.7%)
1 (1.4%)
Anti-HCV positive
6 (7.5%)
2 (2.8%)
0
0
6 (7.5%)
2 (2.8%)
HGV RNA positive /Anti-HCV positive
ALT (> 41 IU/I)
HGV: Hepatitis G virus, anti-HCV: Antibody to hepatitis C, ALT: Serum alanine aminotransferase.
86
Turk J Haematol 2003;20(2):85-90
Prevalence of Hepatitis G Virus in Blood Donors and Recipients
above #G75 antisense primers were used to synthesize
first-round RT-PCR product of 242 bp size of HGV virus. From this first-round PCR product, 5’-GGT CAT
CCT GGT AGC CAC TAT AGG-3’(#G134) sense and
5’-AAG AGA GAC AAT GAA GGG CGA CGT3’(#G131) nested primers were used to amplify a second-round PCR product of 208 bp.
Marker of hepatitis C: The prevalence of anti-HCV
simultaneously tested in the same group of patients and
controls. Anti-HCV determined by a third-generation
enzyme-linked immunoabsorbent assay (HCV EIA,
Abbott Laboratories, North Chicago, Illinois). Conventional liver biochemical tests done using a multiple auto analyzer. The prevalence of anormal liver function
tests was defined as an elevated serum alanine aminotransferase (ALT; above 41 IU/liter, which was previously determined in routine biochemistry laboratory).
Statistical analyses: The one-way ANNOVA test was
used to estimate the differences of age distribution
among groups and between sexes. Differences in the
frequency with which HGV RNA and anti-HCV were
found in the study groups were using Chi-square test.
Odds ratios were calculated to compare the odds of the
group with the lowest prevalence and test-based 95%
confidence intervals (CI) were done.
RESULTS
The mean age and the sex ratio were not significantly different for these two groups (respectively, p>
0.05; p> 0.05). HGV RNA was detected in three of the
patients, and in one of the controls. The prevalence of
HGV RNA in patient group was not significantly higher than control group (3.75%, 1.4%; chi-square p>
0.710). A patient who had received blood components
shows a risk of bearing HGV RNA 2.68 times higher
(95% CI: 0.274-26.451) than a matched control. AntiHCV was detected in six (7.5%), of the patient group
and in two (2.8%) of the control group. The prevalence of anti-HCV in patient group was not significantly
higher in control group (p> 0.170). A patient who had
received blood components shows a risk of bearing anti-HCV 5.59 times higher (95% CI: 0.657-47.659) than
a matched control. HGV and HCV coinfection was not
observed in both patient and control groups.
Mean SD ± values of serum ALT levels were found
to be 39.4 ± 19.2 IU/L in patient group and 30.1 ± 6.6
IU/L in control group. When compared to those of
control group, serum ALT levels were significantly
Turk J Haematol 2003;20(2):85-90
Kaya H, Erdem F, Polat MF, Kýký Ý, Gündoðdu M, Özçiçek F.
higher in patient group (p< 0.0001). Serum ALT levels
were detected above cut off value in 10 of the patients
and six of the controls. Serum ALT was not elevated in
both groups who have HGV RNA positivity. Serum
ALT was elevated in two patients with anti-HCV, but
the control with anti-HCV had normal ALT level.
DISCUSSION
Despite limited diagnostic methods, researches have attempted to determine the prevalence of HGV infection in various populations. There is little information on the prevalence of HGV among various populations in the world. In the literature, the prevalence of
HCV RNA among nonremunerated blood donor populations was reported 1.9%-2.3% in Germany, 2.6%4.2% in France, 2.25% in the United Kingdom, 1%1.7% in the United States, 1.6% in Southern Sweden,
and 0.9%-1.2% in Japan[5,7-9,11-15].
Several reports indicate even higher prevalence
among residents in South America (9%) and Africa
(10.4%)[16,17]. Moreover, the HGV infection was reported highly prevalent among the Jewish population
in Uzbekistan (10.9%)[18]. In the study, the prevalence
of HGV infection (1.4%) is similar of some others. The
controversial data of authors may be due to different
study design, geographical differences, or to in significant associations due to the small number of individuals examined.
In the literature, increased prevalence of HGV virus
was reported in subjects such as haemodialysed patient
(6.9%-16%), haemophiliacs (14.3%-35.2%), thalassemics (35%), intravenous drug users (25%-28.8%) and
patients with aplastic anemia (26.3%)[2,7,8,19-22].
Such data suggest that the transmission of HGV is
primarily by transfusion of contaminated blood components. Parenteral route was not the only source of
HGV infection, however. The HGV RNA detection in
the patients with no transfusion history and with no other risks for parenteral exposure could be related to the
prevalence of HGV infection in the normal blood donor population[5,6,23]. Also, a high prevalence of HGV
has been detected in nondrug-addict homosexuals
(13.4%) and prostitutes (13.9%), which provide strong
evidence of its spread via sexual intercourse[24]. This
would suggest that HGV is transmitted by other unknown means, similar to HCV.
87
Kaya H, Erdem F, Polat MF, Kýký Ý, Gündoðdu M, Özçiçek F.
The prevalence of HGV RNA (3.75%) in patients
receiving blood components in this study was higher
than control (1.4%), but it was not statistically different
(p> 0.05). The prevalence of HGV RNA in patients receiving blood components in this study is lower than
the prevalence reported in literature[19-22]. In a similar
study at our country, the HGV RNA positivity was detected one of the 56 patients undergoing haemodialysis[25].
If HGV appears to be broadly distributed geographically, its prevalence could differ both in patients who
had received blood components and in blood donors in
various geographic area, as is the case for other transfusion-transmissible hepatitis virus. The lower prevalence of HGV RNA in patients receiving blood components in this study could explain the low prevalence of
HGV infection in our geographic area. Also, this difference may be related to number of units transfused.
This study failed to show any relationship between
number of blood transfusions and HGV-RNA positivity due to the limited number of patients in this study.
HGV infection can be diagnosed only by detecting
viremia by reverse-transcription polymerase chain reaction. This assay is highly sensitivite but has several
intrinsic problems. The sensitivity of HGV assays depends on the choice of primers, save condition of serum samples, and presence or absence of contamination. These factors can result in both false-positivite and
false-negative results and might explain some of the reported differences in the prevalence of HGV infection
in similar populations[3].
Prevalence of Hepatitis G Virus in Blood Donors and Recipients
lationship between HGV and hepatitis, although there
is a report associating a strain of HGV with fulminate
hepatitis[27-28]. Many other studies have also shown
that HGV has no impact in the clinical course of coexistent HCV infection[4,6,8,13,20]. In this series, HGVinfected subjects in both groups have a normal serum
ALT. None of them had any signs or symptoms of liver
disease. In this study we also did not show any relationship between HGV and liver injury.
In conclusion, although blood components are
most important risk factor for the transmission of HGV
infection, this study showed that the prevalence of
HGV RNA in patients receiving blood components
was higher (3.75%) than control (1.4%), but it was not
statistically different. Further studies should be done to
ascertain the geographical distribution in general population and in patients who had received blood components.
REFERENCES
1.
2.
We amplified 5’-UTR to this reason. The sensitivity of PCR assays using 5’ UTR primers was 10 to
100 times more likely to detect HGV RNA than that of
NS3 and E2 primers[26].
3.
4.
The reported detection rates of HGV RNA among
patients infected with HCV have revealed HGV co-infection or super infection in the 5 to 20%[6]. However,
we found no HGV RNA in the anti-HCV positive group. Recent large-scale studies have found no causal re-
88
5.
Moriyama K, Okamura T, Nakano S. Hepatitis GB virus
C genome in the serum of aplastic anaemia patients receiving frequent blood transfusions. Br J Haematol
1997;96:864-7.
Brown KE, Wong S, Young NS. Prevalence of GBVC/HGV, a novel “hepatitis” virus, in patients with aplastic
anaemia. Br J Haematol 1997;97:492-6.
Cheung R, Keeffe EB. Hepatitis G virus: Clinical relevance and responsiveness to interferon. Am J Gastroenterol 1997;92:1957-61.
Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R,
Shih JW, Kim JP. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver
disease. N Engl J Med 1997;336:747-54.
Yoshikawa A, Fukuda S, Itoh K, Kosaki N, Suzuki T, Hirakawa K, Nakao H, Inoue T, Fukuda M, Okamoto H.
Infection with hepatitis G virus and its strain variant, the
GB agent (GBV-C), among blood donors in Japan.
Turk J Haematol 2003;20(2):85-90
Kaya H, Erdem F, Polat MF, Kýký Ý, Gündoðdu M, Özçiçek F.
Prevalence of Hepatitis G Virus in Blood Donors and Recipients
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Transfusion 1997;37:657-63.
Tan D, Matsumoto A, Conry-Cantilena C, Melpolder JC,
Shih JW, Leuther M, Hess G, Gibble JW, Ness PM, Alter HJ. Analysis of hepatitis G virus (HGV) RNA, antibody to HGV envelope protein, and risk factors for blood donors coinfected with HGV and hepatitis C virus. J
Infect Dis 1999; 179:1055-61.
Nübling CM, Bialleck H, Fursch AJ, Scharrer I,
Schramm W, Seifried E, Schmidt U, Staszewski S, Lower J. Frequencies of GB virus C/hepatitis G virus genomes and of specific antibodies in German risk and nonrisk populations. J Med Virol 1997;53:218-24.
Feucht HH, Zöllner B, Polywka S, Knodler B, Schröter
M, Nolte H, Laufs R. Prevalence of hepatitis G viremia
among healthy subjects, individuals with liver disease,
and persons at risk for parenteral transmission. J Clin
Microbiol 1997;35:767-8.
Loiseau P, Mariotti M, Corbi C, Ravera N, Girot R, Thauvin M, Portelette E, Mariette X, Roudot-Thoraval F,
Benbunan M, Lefrére JJ. Prevalence of hepatitis G virus
RNA in French blood donors and recipients. Transfusion
1997;37:645-50.
Watanabe T, Ishiguro M, Kametani M, Sugai Y, Takakuwa K, Akahane Y, Masuko K, Shimizu M, Kojima M,
Fujita K, Tsuda F, Okamoto H. GB virus C and hepatitis
C virus infections in hemodialysis patients in eight Japanese centers. Nephron 1997;76: 171-5.
Cantaloube JF, Gallian P, Biagini P, Attoui H, Escher J,
Zappitelli JP, Delord Y, de Micco P, de Lamballerie X.
Prevalence of GB virus type C/hepatitis G virus RNA
and anti-E2 among blood donors in Southeastern France.
Transfusion 1999;39:95-102.
Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE,
Krawczynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, Karayiannis P, Fung K, Nakatsuji
Y, Shih JW, Young L, Piatak M Jr, Hoover C, Fernandez
J, Chen S, Zou JC, Morris T, Hyams KC, Ismay S, et al.
Molecular cloning and disease association of hepatitis G
virus: A transfusion-transmissible agent. Science
1996;271:505-8.
Blair CS, Davidson F, Lycett C, McDonald DM, Haydon
GH, Yap PL, Hayes PC, Simmonds P, Gillon S. Prevalence, incidence, and clinical characteristics of hepatitis
G virus/GB virus C infection in Scottish blood donors.
J Infect Dis 1998;178:1779-82.
Bjorkman P, Widell A, Veress B, Verbaan H, Hoffmann
G, Elmstahl S, Lindgren S. GB virus C/hepatitis G virus
infection in patients investigated for chronic liver disease and in the general population in southern Sweden.
Scandinavian
J
Infect Dis 2001;33:611-7.
Masuko K, Mitsui T, Iwano K, Yamazaki C, Okuda K,
Meguro T, Murayama N, Inoue T, Tsuda F, Okamoto H,
Turk J Haematol 2003;20(2):85-90
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Miyakawa Y, Mayumi M. Infection with hepatitis GB virus C in patients on maintaince hemodialysis. N Engl J
Med 1996;334:1485-90.
Bassit L, Kleter B, Ribeiro-dos-Santos G, Maertens G,
Sabino E, Chamone D, Quint W, Saez-Alquezar A. Hepatitis G virus: Prevalence and sequence analysis in blood donor of Sao Paulo, Brazil. Vox Sang 1998;74:83-7.
Tucker TJ, Louw SJ, Robson SC, Isaacs S, Kirsch RE.
High prevalence of GBV-C hepatitis G virus infection in
a rural South African population. J Med Virol
1997;53:225-8.
Kato T, Mizokami M, Nakano T, Kondo Y, Ohba K, Orito E, Ueda R, Mukaide M, Gurtsevitch V, Syrtsev A, Ruzibakiev R, Abdurakhnamov M, Yamashita M, Hayami
M. High prevalence of GB virus C/hepatitis G virus infection among the Jewish population in Uzbekistan. Virus Research 1997;48:81-7.
Hayashi J, Furusyo N, Sawayama Y, Kishihara Y, Kawakami Y, Ariyama I, Etoh Y, Kashiwagi S. Hepatitis G virus in the general population and in patients on hemodialysis. Dig Dis Sci 1998;43:2143-8.
Lamproye A, Delwaide J, Vaira D, Maggipinto G, Gèrard C, Sondag-Thull D, Rentier B, Rorive G, Belaiche
J. Prevalence of hepatitis G virus in a haemodialysis
unit. Acta Gastroenterologica Belgica 1999;62:13-5.
Kondili LA, Chionne P, Dettori S, Badolato MC, Grosso
A, Vania A, Rapicetta M. GB virus/hepatitis G virus exposure in Italian pediatric and young adult thalassemic patients. Infection 2001;29:219-21.
Wu RR, Mizokami M, Cao K, Nakano T, Ge XM, Wang
SS, Orito E, Ohba K, Mukaide M, Hikiji K, Lau JY, Lino S. GB virus C/hepatitis G virus infection in Southern
China.
J
Infect Dis 1997;175:168-71.
Feucht HH, Schröter M, Zöllner B, Polywka S, Laufs R.
Age-dependent acquisition of hepatitis G virus/GB virus
C in a nonrisk population: Detection of the virus by antibodies. J Clin Mic 1999;37:1294-7.
Rubio A, Rey C, Sánchez-Quijano A, Leal M, Pineda
JA, Lissen E, del Rocio V, Spain S, Hess G. Is hepatitis
G virus transmitted sexually? JAMA 1997; 277:532-3.
Mass MR, Saðlamkaya U, Kubar A, Çolakoðlu M, Ateþkan Ü, Nalbant S, et al. Hepatitis G virus infection
among patients undergoing hemodialysis. Gut
1997;41(Suppl 3):A130 (6th UEGW Poster Presentations).
Kao J, Chen D. GB virus-C/hepatitis G virus infection in
Taiwan: A virus that fails to cause a disease? J Biomed
Sci 1999;6:220-5.
Yoshiba M, Okamoto H, Mishiro S. Detection of the
GBV-C hepatitis virus genome in serum from patients
with fulminant hepatitis of unknown etiology. Lancet
1995;346:1131-2.
89
Kaya H, Erdem F, Polat MF, Kýký Ý, Gündoðdu M, Özçiçek F.
Prevalence of Hepatitis G Virus in Blood Donors and Recipients
28. Fiordalisi G, Zanella I, Mantero G, Bettinardi A, Stellini R, Paraninfo G, Cadeo G, Primi D. High prevalence of
GB virus C infection in a group of Italian patients with
hepatitis
of
unknown
etiology.
J
Infect Dis 1996;174:181-3.
Address for Correspondence:
Hasan KAYA, MD
Atatürk Üniversitesi Týp Fakültesi
Dahiliye Anabilim Dalý
25240, Erzurum, TURKEY
e mail: hkaya@atauni.edu.tr
90
Turk J Haematol 2003;20(2):85-90